Altimmune, Inc. (ALT)
NGM · Healthcare · Biotechnology
$3.27
-0.61%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$636.1M
Shares Outstanding
194.5M
P/S (TTM)
20,518x
Exchange
NGM
Currency
USD
About Altimmune, Inc.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 5K | 26K | 0.00 | 0.00 |
| Operating Income | (20.9M) | (28.9M) | (24.2M) | (26.2M) |
| Net Income | (19.0M) | (27.4M) | (22.6M) | (22.8M) |
| Diluted EPS | $-0.21 | $-0.27 | $-0.18 | $-0.12 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | (68K) | 426K | 20K | 41K |
| Operating Income | (87.7M) | (83.5M) | (103.2M) | (94.5M) |
| Net Income | (84.7M) | (88.4M) | (95.1M) | (88.1M) |
| Diluted EPS | $-1.81 | $-1.66 | $-1.34 | $-1.00 |